Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.
“Upadacitinib has already shown efficacy in a phase 2/3 study in ankylosing spondylosis patients with inadequate response to NSAIDs, and in another phase 3 study in AS patients who had an inadequate response to biologic DMARDs,” Atul Deodhar, MD, of the Oregon Health & Science University, in Portland, told Healio. “We wanted to investigate its efficacy in non-radiographic axial SpA